Severe cutaneous adverse reactions
Ugeskrift for Læger · 2026
DOI: 10.61409/v08250696 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Ugeskrift for Læger, 2026. Verfasst von Anders Benjamin Rønsholdt und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hudafdeling I og Allergicentret, Odense Universitetshospital. Hauptthemen laut MEDLINE: Drug Eruptions.
Abstract (Originalsprache)
Severe cutaneous adverse reactions are rare, potentially life-threatening T-cell-mediated drug reactions. They present with rapid onset skin lesions and may involve the mucosa and multiple organs. This review finds that early identification, drug withdrawal, supportive care, and immunomodulatory therapy are essential. JAK inhibitors have shown promise in Stevens-Johnson’s syndrome/toxic epidermal necrolysis, IL-5 blockade is being tested for drug reaction with eosinophilia and systemic symptoms; and IL-36 inhibition, may be a future option for acute generalised exanthematous pustulosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Hudafdeling I og Allergicentret, Odense Universitetshospital.
- Afdeling for Allergi, Hud- og Kønssygdomme, Københavns Universitetshospital - Gentofte Hospital.
Zitieren
APA
Rønsholdt, A. B., Stockmann, A., Zachariae, C., & Lorentzen, H. F. (2026). Severe cutaneous adverse reactions. Ugeskrift for Læger. https://doi.org/10.61409/v08250696
Vancouver
Rønsholdt AB, Stockmann A, Zachariae C, Lorentzen HF. Severe cutaneous adverse reactions. Ugeskrift for Læger. 2026. doi:10.61409/v08250696
BibTeX
@article{Rnsholdt2026,
author = {Rønsholdt, Anders Benjamin and Stockmann, Anne and Zachariae, Claus and Lorentzen, Henrik Frank},
title = {Severe cutaneous adverse reactions},
journal = {Ugeskrift for Læger},
year = {2026},
doi = {10.61409/v08250696}
}
EUVIMED